<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Hepatol Bed Bench</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Hepatol Bed Bench</journal-id><journal-id journal-id-type="publisher-id">GHFBB</journal-id><journal-title-group><journal-title>Gastroenterology and Hepatology From Bed to Bench</journal-title></journal-title-group><issn pub-type="ppub">2008-2258</issn><issn pub-type="epub">2008-4234</issn><publisher><publisher-name>Shaheed Beheshti University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26171138</article-id><article-id pub-id-type="pmc">4495427</article-id><article-id pub-id-type="publisher-id">GHFBB-8-S54</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>
<bold>The </bold>
<bold><italic>Helicobacter pylori</italic></bold>
<bold> eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study </bold>
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ehsani-Ardakani</surname><given-names>Mohammad Javad</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sedaghat</surname><given-names>Meghdad</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eslami</surname><given-names>Gyti</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohaghegh Shalmani</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Emam Hossein Hospital, </italic><italic>Shahid Beheshti University of Medical Sciences, Tehran, Iran</italic></aff><aff id="aff2"><label>2</label><italic>Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran</italic></aff><author-notes><corresp id="cor">Reprint or Correspondence: Meghdad Sedaghat MD. Emam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: msreihan@gmail.com</corresp></author-notes><pub-date pub-type="ppub"><season>Spring</season><year>2015</year></pub-date><volume>8</volume><issue>Suppl1</issue><fpage>S54</fpage><lpage>S59</lpage><permissions><copyright-statement>&#x000a9;2015 RIGLD, Research Institute for Gastroenterology and Liver Diseases</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Aim:</title><p>The aim of this study was to evaluate the <italic>Helicobacter pylori</italic> eradication in the group receiving standard -dose twice a day for two weeks and continue taking amoxicillin for 4 weeks.</p></sec><sec><title>Background:</title><p>
<italic>Helicobacter pylori</italic> is the major etiological cause of chronic gastritis, gastric and duodenal ulcers, gastric cancer and lymphoma. Therefore, patients should be treated after diagnosis <italic>of H. pylori</italic> infection. </p></sec><sec><title>Patients and methods:</title><p>A total of 66 consecutive patients with rapid urease test during endoscopy or biopsy positive for <italic>H. pylori </italic>were enrolled in this clinical trial study during 2013-2014.&#x000a0;Patients were divided randomly into two groups. Group&#x000a0;A (standard&#x000a0;dose) received omeprazole (20 mg), amoxicillin (1 g), and clarithromycin (500 mg), all two times a day for two weeks.&#x000a0;Group&#x000a0;B received standard&#x000a0;dose like group A and in patients with <italic>H.pylori</italic> infection amoxicillin were continued for 4 weeks. After completion of treatment, patients did not receive any treatment for a month and then stool antigen was performed to evaluate the <italic>H.pylori</italic>. </p></sec><sec><title>Results:</title><p>The rate of successful HP eradication was significantly higher in group A (90.9% V.s 63.6%; p=0.017). Inflation and bitter mouth were found in 8 and 13 patients in group A and 7 and 9 patients in group B, respectively. The incidence of adverse effects was the same (p=0.437). </p></sec><sec><title>Conclusion:</title><p>Increased duration of antibiotic therapy to four weeks significantly raises the rate of successful HP eradication with standard triple therapy without significant increase in adverse effects. </p></sec></abstract><kwd-group><title>Key Words</title><kwd><italic>Helicobacter pylori</italic></kwd><kwd>Amoxicillin</kwd><kwd>Clarithromycin</kwd><kwd>Omeprazole</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>
<italic>Helicobacter pylori</italic> (HP) is the most common chronic bacterial infection in humans (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). It is estimated that 60% of the world population is infected with HP infection (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>). The incidence of HP infection in the United States, as well as developed and developing countries has been reported between 30% and 80% respectively (<xref rid="B4" ref-type="bibr">4</xref>). It is indicated that more than 70% of infected cases are asymptomatic (<xref rid="B5" ref-type="bibr">5</xref>). In the United States, its prevalence is influenced by age and approximately 50% of infected cases are around 60 years old and 25% of patients are 30 years old (<xref rid="B1" ref-type="bibr">1</xref>). Low incidence of HP infection among children in developed countries is due to improvements in lifestyle and increased use of antibiotics (<xref rid="B6" ref-type="bibr">6</xref>). </p><p>The HP infection is prevalent worldwide and associated with many gastrointestinal problems (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B10" ref-type="bibr">10</xref>). In particular, it has been shown that HP infection plays a role in the pathogenesis of peptic ulcers, chronic/active gastritis and gastric cancer (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B11" ref-type="bibr">11</xref>-<xref rid="B22" ref-type="bibr">22</xref>). In this situation patients should be treated if the <italic>H.pylori</italic> infection diagnosed. HP eradication is the main treatment of peptic ulcer disease and other gastroduodenal disorders (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B23" ref-type="bibr">23</xref>-<xref rid="B27" ref-type="bibr">27</xref>).Studies have shown that eradication of HP is accompany by reducing the severity of gastritis and recurrence peptic ulcer rate (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Appropriate treatment of HP infection is unknown (<xref rid="B1" ref-type="bibr">1</xref>). In 1994, NIH (National Institutes of Health) reported that patients with peptic ulcer disease and <italic>H.pylori</italic> infection require treatment with antimicrobial agents (<xref rid="B2" ref-type="bibr">2</xref>). Therefore, in the last decades the standard 3-drug regimen including amoxicillin, clarithromycin, and metronidazole are widely used in many countries as a first step regimen for HP eradication (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B30" ref-type="bibr">30</xref>-<xref rid="B38" ref-type="bibr">38</xref>). </p><p>In recent year&#x02019;s eradication of HP infection in some cases were failed due to increasing resistance to clarithromycin and metronidazole (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>). In different clinical trials, 61 to 93% eradication rate of <italic>H. pylori</italic> has been reported using two, three and four drugs regimes, whereas in the placebo-control studies eradication rate of <italic>H. pylori</italic> has been shown in 64-69% of cases using two- and three-drug regimen. </p><p>In this study, the eradication rate of <italic>H. pylori</italic> in the two groups, including group A receiving the standard regimen and group B received standard&#x000a0;dose like group A and in patients with <italic>H.pylori</italic> infection amoxicillin were continued for 4 weeks were evaluated. </p></sec><sec sec-type="methods"><title>Patients and Methods</title><p>In this clinical trial, patients with <italic>Helicobacter pylori</italic> infection during the period of 2013-14were recruited the study. Inclusion criteria, ,were including stopping using bismuth or antibiotics within 4 weeks before entry the study, no history of eradication of <italic>H.pylori</italic> or gastric cancer in the endoscopy report, no history of allergy to amoxicillin and omeprazole, no previous gastric surgery. </p><p>Invasive tests and/or rapid urease test were the first to be used in the diagnosis of <italic>H. pylori</italic> infection.</p><p>Then the data of the infected patients were recorded during endoscopy. </p><p>Following ethical and research committee approval, subjects gave their informed consent and was recruited into this study. Then the data of patients were collected using a valid questionnaire and divided randomly into two groups. For group A, a standard triple therapy for 2 weeks and then continued with 1000 mg amoxicillin every 12 hours for the next 2 weeks were administered. For group B, standard triple therapy for 2 weeks and then continued placebo every 12 hours for the next two weeks were administered. </p><p>It should be noted that omeprazole/amoxicillin/clarithromycin&#x000a0;(Rx) every 12 hours was considered as the standard regimen in this study. After completion of treatment, patients did not receive any treatment for a month and then <italic>H.pylori</italic> stool antigen test was evaluated. Patients with drug intolerance were excluded. Finally, data regarding <italic>H. pylori</italic> eradication after treatment were collected and compared between the two groups. It should be noted that in order to reduce bias in the study, lab technicians were blind to the duration of treatment, dose of the drugs and type of regimen. </p><p>
<bold>Statistical analysis</bold>
</p><p>In this study, non-probability convenience sampling was used. To compare quantitative data between the two groups, independent samples t-test and for qualitative data Fisher's exact test or chi-square test were used. Statistical analyzes were performed using the SPSS software ver.16 and P&#x0003c;0.05 was considered as significant. </p></sec><sec sec-type="results"><title>Results</title><p>Out of 80 patients, 14 patients found it hard and difficult to continue and subsequently were withdrawn from study and eventually study was conducted on 66 patients in the two groups. The mean age of patients in group A was 44.6 &#x000b1; 14.9 years (range 23-77) and in group B was 41.8 &#x000b1; 14.6 years (range 17-78). The difference between the two groups was not statistically significant (p=0.39). In the group A, 18 cases were men and in the placebo group, 16 were male. Distribution of comorbidities, the main complaint, smoking status and endoscopic findings of patients in both groups were presented in <xref ref-type="table" rid="T1">Table 1</xref> and show that there is no significant difference between the two groups (p&#x0003e;0.05).</p><p>According to the study, we found that HP infection was successfully eradicated in 30 patients (90.9%) and 21 (63.6%) in group A and group B respectively. In this case, the difference between the two groups was statistically significant (p=0.01).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of comorbidities, patient complaints, smoking and endoscopic findings between the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Group A</th><th align="center" rowspan="1" colspan="1">Group B</th><th align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Comorbidities</td><td align="left" rowspan="1" colspan="1">Without Comorbidities</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="3" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">dyspepsia</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">GERD</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="9" colspan="1">Main complication</td><td align="left" rowspan="1" colspan="1">Epigaster pain</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="9" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Melena</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Difficulty swallowing</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Bloating</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Burning</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart burn</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Bloating</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight loss</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="4" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">Active smokers</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="4" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Passive smokers</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Quit smoking</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonsmokers</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="5" colspan="1">Endoscopy findings</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="5" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Ulcer</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Duodenal ulcer</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastritis</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">Scrape pulp</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td></tr></tbody></table></table-wrap><p>The only treatment-related side effect seen in the most of patients were bloating and bitter mouth. The incidence of these side effects was similar in the two groups (p=0.437). The main complaint of patients in both groups was epigastric pain, which is presented in 23 and 21 subjects in group A and B respectively. In both groups, the most common endoscopic findings were gastritis. </p></sec><sec sec-type="discussion"><title>Discussion</title><p>The result of this study showed that increase the duration of amoxicillin usage is significantly associated with an increase in the success rate of HP infection eradication. In addition, we found that this method is a safe method and treatment-related side effects are as similar as common methods of treatment. </p><p>Eradication of HP infection is one of the fundamental challenges in GI science. Omeprazole, clarithromycin and amoxicillin regimens are widely used for HP eradication due to high efficacy and limited side effects (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B39" ref-type="bibr">39</xref>). On the other hand due to unsuccessful treatment of HP infection, researchers recommended the newer therapies such as quadruple therapy. There are several factors that can affect the success rate of HP eradication. One of the most important factors is the increasing antibiotic resistance, which raised these days and knowledge of the antibiotic resistance pattern can greatly assist in providing the most appropriate treatment strategy (<xref rid="B40" ref-type="bibr">40</xref>-<xref rid="B42" ref-type="bibr">42</xref>). It is very difficult to determine and assess the resistance of HP regularly, because the concentration of the antibiotic should be considered in gastric mucosal not in the blood (<xref rid="B40" ref-type="bibr">40</xref>).</p><p>Some researchers believe that in spite of using the same treatment regimens with Western countries, the success rate of HP infection eradication is much lower and therefore, the recurrence rate is much higher (<xref rid="B43" ref-type="bibr">43</xref>). To control the HP resistance, some researchers suggested increasing the duration of antibiotic treatment. </p><p>For instance, Fallone et al. recommended duration of proton&#x000a0;pump&#x000a0;inhibitor&#x000a0;triple&#x000a0;therapy should be increased from seven to 14 days (<xref rid="B44" ref-type="bibr">44</xref>). They concluded that an increased duration of treatment with triple therapy with PPI could significantly increase the success rate of HP eradication without being accompanied by an increased incidence of side effects. Also, Greenberg et al. performed randomized trial of experimental 14-day triple, 5-day concomitant, and 10-day sequential therapies for <italic>H. pylori</italic> eradication (<xref rid="B45" ref-type="bibr">45</xref>). The result of their trial showed that standard two-week triple-drug therapy is more effective than 5-day concomitant or 10-day sequential four-drug regimens as an experimental therapy for <italic>H pylori</italic> infection. Iwa&#x00144;czak suggested that to obtain better results of the eradication, the&#x000a0;treatment&#x000a0;should be prolonged from 7 to 10 or even 14 days, and it is necessary to increase the dose of antibiotics (<xref rid="B46" ref-type="bibr">46</xref>). However, despite these studies, Yoon and colleagues demonstrated that an increased duration of treatment did not increase the success of HP eradication due to the rapid increase in bacterial resistance. (<xref rid="B47" ref-type="bibr">47</xref>)</p><p>In the present study, we examined the effect of increasing treatment duration from 14 to 28 days, and success rate of HP eradication. We have observed that increasing the duration of treatment was associated with a significantly increased HP eradication and as a result, successful treatment was detected in approximately 90% of patients in group-A. However, the high percentage of patients with placebo failed to treatment (36.4%) and this may indicate that the increased efficiency of antibiotic therapy is associated with an increased success rate of HP eradication. These findings are in accordance with previous studies that suggest prolonged antibiotic therapy can play an important role in increasing the success rate of HP eradication. This is an effective treatment and has been recommended by authors.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydemir</surname><given-names>S</given-names></name><name><surname>Boyacioglu</surname><given-names>S</given-names></name><name><surname>Gur</surname><given-names>G</given-names></name><name><surname>Demirbilek</surname><given-names>M</given-names></name><name><surname>Can</surname><given-names>FK</given-names></name><name><surname>Korkmaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin</article-title><source> World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>842</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15682477</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><collab>NIH Consensus Conference</collab><article-title>Helicobacter pylori in peptic ulcer disease NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease</article-title><source> JAMA</source><year>1994</year><volume>272</volume><fpage>65</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">8007082</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>XL</given-names></name><name><surname>Cao</surname><given-names>DZ</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients</article-title><source> World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>2477</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">15832421</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khedmat</surname><given-names>H</given-names></name><name><surname>Ahmadzad-Asl</surname><given-names>M</given-names></name><name><surname>Amini</surname><given-names>M</given-names></name><name><surname>Lessan-Pezeshki</surname><given-names>M</given-names></name><name><surname>Einollahi</surname><given-names>B</given-names></name><name><surname>Pourfarziani</surname><given-names>V</given-names></name><etal/></person-group><article-title>Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients</article-title><source> Transplant Proc</source><year>2007</year><volume>39</volume><fpage>1003</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17524875</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Blaser</surname><given-names>MJ</given-names></name><name><surname>Atherton</surname><given-names>JC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name><etal/></person-group><source>Helicobacter pylori infections</source><year>2008</year><edition>17th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group><source>Harrison's Principles of internal medicine</source><year>2008</year><edition>17th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill Co, Inc</publisher-name><fpage>1855</fpage><lpage>72</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cave</surname><given-names>DR</given-names></name></person-group><article-title>Transmission and epidemiology of Helicobacter pylori</article-title><source> Am J Med</source><year>1996</year><volume>100</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">8579078</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>WL</given-names></name><name><surname>Fendrick</surname><given-names>AM</given-names></name><name><surname>Cave</surname><given-names>DR</given-names></name><name><surname>Peura</surname><given-names>DA</given-names></name><name><surname>Garabedian-Ruffalo</surname><given-names>SM</given-names></name><name><surname>Laine</surname><given-names>L</given-names></name></person-group><article-title>Helicobacter pylori-related disease: guidelines for testing and treatment</article-title><source> Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>1285</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">10809031</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><collab>The European Helicobacter pylori Study Group</collab><article-title>Current European concepts in the management of Helicobacter pylori infectionThe Maastricht Consensus Report</article-title><source> Gut</source><year>1997</year><volume>41</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">9274464</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sezer</surname><given-names>S</given-names></name><name><surname>Ibi&#x0015f;</surname><given-names>A</given-names></name><name><surname>Ozdemir</surname><given-names>BH</given-names></name><name><surname>Ozdemir</surname><given-names>FN</given-names></name><name><surname>K&#x000fc;lah</surname><given-names>E</given-names></name><name><surname>Boyacio&#x0011f;lu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of Helicobacter pylori infection with nutritional status in hemodialysis patients</article-title><source> Transplant Proc</source><year>2004</year><volume>36</volume><fpage>47</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15013297</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luzza</surname><given-names>F</given-names></name><name><surname>Imeneo</surname><given-names>M</given-names></name><name><surname>Maletta</surname><given-names>M</given-names></name><name><surname>Mantelli</surname><given-names>I</given-names></name><name><surname>Tancre</surname><given-names>D</given-names></name><name><surname>Merando</surname><given-names>G</given-names></name><etal/></person-group><article-title>Helicobacter pylori specific IgG in chronic haemodialysis patients: Relationship of hypergastrinaemia to positive serology</article-title><source> Nephrol Dial Transplant</source><year>1996</year><volume>11</volume><fpage>120</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">8649619</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsonnet</surname><given-names>J</given-names></name><name><surname>Friedman</surname><given-names>GD</given-names></name><name><surname>Vandersteen</surname><given-names>DP</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Vogelman</surname><given-names>JH</given-names></name><name><surname>Orentreich</surname><given-names>N</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection and the risk of gastric carcinoma</article-title><source> N Engl J Med</source><year>1991</year><volume>325</volume><fpage>1127</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">1891020</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Lew</surname><given-names>GM</given-names></name><name><surname>Klein</surname><given-names>PD</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Evans</surname><given-names>DJ Jr</given-names></name><name><surname>Saeed</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer</article-title><source> Ann Intern Med</source><year>1992</year><volume>116</volume><fpage>705</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">1558340</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieramico</surname><given-names>O</given-names></name><name><surname>Zanetti</surname><given-names>MV</given-names></name><name><surname>Innerhofer</surname><given-names>M</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name></person-group><article-title>Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial</article-title><source> Helicobacter</source><year>1997</year><volume>2</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">9432335</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misiewicz</surname><given-names>JJ</given-names></name></person-group><article-title>Current insights in the pathogenesis of Helicobacter pylori infection</article-title><source> Eur J Gastroenterol Hepatol</source><year>1995</year><volume>7</volume><fpage>701</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">8590167</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyle</surname><given-names>FA</given-names></name></person-group><article-title>Helicobacter pylori: Current perspectives</article-title><source> J Clin Gastroenterol</source><year>1991</year><volume>13</volume><fpage>S114</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">1940186</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Yamakido</surname><given-names>M</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection and the development of gastric cancer</article-title><source> N Engl J Med</source><year>2001</year><volume>345</volume><fpage>784</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11556297</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>RJ</given-names></name><name><surname>Girardi</surname><given-names>LS</given-names></name><name><surname>Turney</surname><given-names>EA</given-names></name></person-group><article-title>Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review</article-title><source> Gastroenterology</source><year>1996</year><volume>110</volume><fpage>1244</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">8613015</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wotherspoon</surname><given-names>AC</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name><name><surname>de</surname><given-names>Boni M</given-names></name><name><surname>Spencer</surname><given-names>J</given-names></name><name><surname>Isaacson</surname><given-names>PG</given-names></name></person-group><article-title>Antibiotic treatment for low-grade gastric MALT lymphoma</article-title><source> Lancet</source><year>1994</year><volume>343</volume><lpage>1503</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>BJ</given-names></name><name><surname>Warren</surname><given-names>JR</given-names></name></person-group><article-title>Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration</article-title><source> Lancet</source><year>1984</year><volume>1</volume><fpage>1311</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">6145023</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaser</surname><given-names>MJ</given-names></name></person-group><article-title>Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation</article-title><source> Gastroenterology</source><year>1992</year><volume>102</volume><fpage>720</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">1732141</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Newell</surname><given-names>DG</given-names></name><name><surname>Fullerton</surname><given-names>F</given-names></name><name><surname>Yarnell</surname><given-names>JW</given-names></name><name><surname>Stacey</surname><given-names>AR</given-names></name><name><surname>Wald</surname><given-names>N</given-names></name><etal/></person-group><article-title>Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation</article-title><source> Br Med J</source><year>1991</year><volume>302</volume><fpage>1302</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">2059685</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsonnet</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>L</given-names></name><name><surname>Gelb</surname><given-names>AB</given-names></name><name><surname>Warnke</surname><given-names>RA</given-names></name><name><surname>Jellum</surname><given-names>E</given-names></name><etal/></person-group><article-title>Helicobacter pylori infection and gastric lymphoma</article-title><source> N Engl J Med</source><year>1994</year><volume>330</volume><fpage>1267</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">8145781</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>JH</given-names></name><name><surname>Peterson</surname><given-names>WL</given-names></name></person-group><article-title>The treatment of Helicobacter pylori infection in the management of peptic ulcer disease</article-title><source> N Engl J Med</source><year>1995</year><volume>333</volume><fpage>984</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7666920</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaty</surname><given-names>HM</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Isaksson</surname><given-names>I</given-names></name><name><surname>Engstrand</surname><given-names>L</given-names></name><name><surname>Pedersen</surname><given-names>NL</given-names></name></person-group><article-title>Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?</article-title><source> Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">10632311</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rokkas</surname><given-names>T</given-names></name><name><surname>Karameris</surname><given-names>A</given-names></name><name><surname>Mavrogeorgis</surname><given-names>A</given-names></name><name><surname>Rallis</surname><given-names>E</given-names></name><name><surname>Giannikos</surname><given-names>N</given-names></name></person-group><article-title>Eradication of Helicobacter pylori reduces the possibility of re-bleeding in peptic ulcer disease</article-title><source> Gastrointest Endosc</source><year>1995</year><volume>4</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7698617</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Take</surname><given-names>S</given-names></name><name><surname>Mizuno</surname><given-names>M</given-names></name><name><surname>Ishiki</surname><given-names>K</given-names></name><name><surname>Nagahara</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Yokota</surname><given-names>K</given-names></name><etal/></person-group><article-title>The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease</article-title><source> Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>1037</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15842576</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>C</given-names></name><name><surname>Hungin</surname><given-names>AP</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Axon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report</article-title><source> Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>167</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">11860399</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashiwagi</surname><given-names>H</given-names></name></person-group><article-title>Ulcers and gastritis</article-title><source> Endoscopy</source><year>2003</year><volume>35</volume><lpage>9</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Bayerd&#x000f6;rffer</surname><given-names>E</given-names></name><name><surname>Diete</surname><given-names>U</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Lind</surname><given-names>T</given-names></name><name><surname>Misiuna</surname><given-names>P</given-names></name><etal/></person-group><article-title>The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer</article-title><source> Aliment Pharmacol Ther</source><year>1999</year><volume>13</volume><fpage>703</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">10383498</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name><name><surname>Kist</surname><given-names>M</given-names></name><name><surname>Leodolter</surname><given-names>A</given-names></name><name><surname>Peitz</surname><given-names>U</given-names></name><name><surname>Strobel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Helicobacter pylori eradication and gastric ulcer healing-comparison of three pantoprazolebased triple therapies</article-title><source> Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><fpage>1125</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12752349</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkey</surname><given-names>CJ</given-names></name><name><surname>Atherton</surname><given-names>JC</given-names></name><name><surname>Treichel</surname><given-names>HC</given-names></name><name><surname>Thjodleifsson</surname><given-names>B</given-names></name><name><surname>Ravic</surname><given-names>M</given-names></name></person-group><article-title>Safety and efficacy of 7-d rabeprazole-and omeprazolebased triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease</article-title><source> Aliment Pharmacol Ther</source><year>2003</year><volume>17</volume><fpage>1065</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12694089</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>R</given-names></name><name><surname>Thomson</surname><given-names>AB</given-names></name></person-group><article-title>Consensus Conference participants Canadian Helicobacter pylori consensus conference</article-title><source> Can J Gastroenterol</source><year>1998</year><volume>12</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">9544410</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misiewicz</surname><given-names>JJ</given-names></name></person-group><article-title>Management of Helicobacter pylori-related disorders</article-title><source> Eur J Gastroenterol Hepatol</source><year>1997</year><volume>9</volume><fpage>S17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9160212</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van</surname><given-names>der Hulst RW</given-names></name><name><surname>Keller</surname><given-names>JJ</given-names></name><name><surname>Rauws</surname><given-names>EA</given-names></name><name><surname>Tytgat</surname><given-names>GN</given-names></name></person-group><article-title>Treatment of Helicobacter pylori infection: A review of the world literature</article-title><source> Helicobacter</source><year>1996</year><volume>1</volume><fpage>6</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">9398908</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Iovene</surname><given-names>MR</given-names></name><name><surname>Russo</surname><given-names>MI</given-names></name><name><surname>Rocco</surname><given-names>A</given-names></name><name><surname>Salerno</surname><given-names>R</given-names></name><name><surname>Cozzolino</surname><given-names>D</given-names></name><etal/></person-group><article-title>Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates</article-title><source> J Clin Pathol</source><year>2008</year><volume>61</volume><fpage>1112</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">18755715</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><etal/></person-group><article-title>A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial</article-title><source> Eur J Gastroenterol Hepatol</source><year>2010</year><volume>22</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">19996977</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Ogasawara</surname><given-names>N</given-names></name><name><surname>Utsumi</surname><given-names>K</given-names></name><name><surname>Kawamura</surname><given-names>N</given-names></name><name><surname>Kamiya</surname><given-names>T</given-names></name><name><surname>Kataoka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin</article-title><source> J Clin Biochem Nutr</source><year>2010</year><volume>47</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">20664731</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazzoli</surname><given-names>F</given-names></name><name><surname>Porro</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>MG</given-names></name><name><surname>Molteni</surname><given-names>M</given-names></name><name><surname>Pazzato</surname><given-names>P</given-names></name><name><surname>Zagari</surname><given-names>RM</given-names></name></person-group><article-title>Treatment of Helicobacter pylori infection Indications and regimens: An update</article-title><source> Dig Liver Dis</source><year>2002</year><volume>34</volume><fpage>70</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11926576</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazzoli</surname><given-names>F</given-names></name><name><surname>Zagari</surname><given-names>RM</given-names></name><name><surname>Pozzato</surname><given-names>P</given-names></name><name><surname>Fossi</surname><given-names>S</given-names></name><name><surname>Ricciardiello</surname><given-names>L</given-names></name><name><surname>Nicolini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Low-doselansoprazole and clarithromycinplusmetronidazole vs full-dose lansoprazole and clarithromycinplus amoxicillin for eradication of Helicobacter pylori infection</article-title><source> Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>153</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">11856090</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megraud</surname><given-names>F</given-names></name></person-group><article-title>Helicobacter pylori resistance to antibiotics: Prevalence, mechanism, detection What&#x02019;s new?</article-title><source> Can J Gastroenterol</source><year>2003</year><volume>17</volume><fpage>S49</fpage><lpage>52</lpage></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megraud</surname><given-names>F</given-names></name></person-group><article-title>Basis for the management of drug-resistant Helicobacter pylori infection</article-title><source> Drugs</source><year>2004</year><volume>64</volume><fpage>1893</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">15329036</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Mohamadnejad</surname><given-names>M</given-names></name><name><surname>Siavoshi</surname><given-names>F</given-names></name><name><surname>Massarrat</surname><given-names>S</given-names></name></person-group><article-title>Treatment of Helicobacter pylori infection in iran: low efficacy of recommended western regimens</article-title><source> Arch Iran Med</source><year>2004</year><volume>7</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallone</surname><given-names>CA</given-names></name><name><surname>Barkun</surname><given-names>AN</given-names></name><name><surname>Szilagyi</surname><given-names>A</given-names></name><name><surname>Herba</surname><given-names>KM</given-names></name><name><surname>Sewitch</surname><given-names>M</given-names></name><name><surname>Martel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada</article-title><source> Can J Gastroenterol</source><year>2013</year><volume>27</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">23862170</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>ER</given-names></name><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Morgan</surname><given-names>DR</given-names></name><name><surname>Torres</surname><given-names>J</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Bravo</surname><given-names>LE</given-names></name><etal/></person-group><article-title>14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial</article-title><source> Lancet</source><year>2011</year><volume>378</volume><fpage>507</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">21777974</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwa&#x00144;czak</surname><given-names>F</given-names></name><name><surname>Iwa&#x00144;czak</surname><given-names>B</given-names></name></person-group><article-title>Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance</article-title><source> Adv Clin Exp Med</source><year>2012</year><volume>21</volume><fpage>671</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">23356205</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Hwang</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate</article-title><source> Helicobacter</source><year>2009</year><volume>14</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19751431</pub-id></element-citation></ref></ref-list></back></article>